The Journal of Thoracic and Cardiovascular Surgery, Vol 96, 806-810, Copyright © 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
Urinary polyamines as markers of cardiac allograft rejection. A clinical evaluation
M Carrier, DH Russell, TP Davis, RW Emery and JG Copeland
Department of Cardiothoracic Surgery, College of Medicine, University of Arizona, Tucson.
Histologic evaluation of endomyocardial biopsy specimens is the current
method of monitoring rejection after cardiac transplantation.
Unfortunately, this technique gives a discontinuous evaluation of the
recipient immunologic status. A noninvasive marker of immunologic
activation and of allograft rejection that would permit a more continuous
monitoring than the biopsy technique would be clinically useful. Urinary
polyamine excretion reflects cellular proliferation or degeneration and, as
a marker of cellular metabolic activity, may also reflect lymphocyte
proliferation and organ rejection. From July 1985 to December 1986, urinary
polyamines were studied in 18 patients during hospitalization for heart and
heart-lung transplantation. Endomyocardial biopsy was performed twice a
week and histologic rejection was characterized by standard criteria.
Urinary specimens were collected daily and analyzed for polyamines by
high-pressure liquid chromatography. Concentrations of acetylputrescine and
total urinary polyamines were significantly higher before the 20 rejection
episodes than before the 80 biopsies yielding negative results. So that
their clinical usefulness could be evaluated, an elevation of polyamines
and a daily level variability of 28% or more was chosen to indicate
increased metabolic cellular activity and to predict rejection in the next
8 days. On the basis of these definitions, the sensitivity of polyamine
assays to predict rejection was 85%, the specificity 88%, and the positive
predictive value 79%. Therefore, serial measurements of urinary polyamines
may provide daily information on the recipient's immunologic status after
cardiac transplantation.